Beacon RNA – The Current Landscape of Lipid Nanoparticles for Drug Delivery
About the report
- 65% of assets utilizing the LNP are still in preclinical development, suggesting interest in leveraging this delivery platform.
- Beacon RNA identifies 352 trials investigating a therapy utilizing LNP delivery technology, including a peak in trial initiation being recorded in 2021.
- Although COVID-19 infection is the most clinically investigated indication amongst the LNP-based therapies, LNP-delivery technologies are also being investigated for the treatment of solid tumours, blood cancers and metabolic diseases.
About Beacon Targeted Therapies
We are a clinical trial and pipeline database solution, designed in partnership with pharmaceutical professionals. We track targeted therapies to provide accurate, in-depth and real-time information in the rapidly evolving landscape of drug development.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements